Recruiting Studies
Advanced SearchData: ClinicalTrials.gov · Source of record for eligibility and locations
Top Cities for Benign Prostatic Hyperplasia Clinical Trials
Benign Prostatic Hyperplasia clinical trials are recruiting across 35 cities. Here are the cities with the most active studies:
Benign Prostatic Hyperplasia Trial Phases
12 research organizations are sponsoring benign prostatic hyperplasia trials.
About Benign Prostatic Hyperplasia
Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that can cause urinary symptoms in men. It becomes increasingly common with age, affecting most men over 50. Treatment includes alpha-blockers, 5-alpha reductase inhibitors, and minimally invasive procedures.
Clinical trials are advancing new treatments for benign prostatic hyperplasia. Currently, 17 studies are recruiting a combined 9,575 participants across the United States. Research is being conducted by 12 organizations including Société Internationale d'Urologie, Northwestern University, Beth Israel Deaconess Medical Center and 9 others.
2026 Benign Prostatic Hyperplasia Research Landscape
As of July 2026, the benign prostatic hyperplasia clinical trial landscape includes 17 actively recruiting studies across 35 cities in the United States. These studies are collectively seeking 9,575 participants, with an average enrollment target of 563 per study.
The research spans multiple phases of development: 8 studies are in NA, 2 studies are in PHASE2, 1 study is in PHASE3. The presence of Phase 3 trials indicates that some benign prostatic hyperplasia treatments are in late-stage testing and may be approaching regulatory review.
Research is being led by 12 different organizations, including Société Internationale d'Urologie, Northwestern University, Beth Israel Deaconess Medical Center, Boston Scientific Corporation, Rivermark Medical, and 7 others. The large number of sponsors reflects significant research interest and investment in benign prostatic hyperplasia treatment advancement.
Geographically, benign prostatic hyperplasia trials are most concentrated in Chicago, Illinois (3 trials); Cleveland, Ohio (3 trials); Los Angeles, California (2 trials); Glenview, Illinois (2 trials); Boston, Massachusetts (2 trials) and 7 other cities.
Featured Benign Prostatic Hyperplasia Studies
Highlighted recruiting studies for benign prostatic hyperplasia, selected by enrollment size and research scope.
BPH Global Registry
Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrel...
Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes
The goal of this project is to use newly developed patient-reported outcomes to improve the clinical care of patients with benign prostatic hyperplasia. The use of new patient-centered tools will improve evaluation and clinical decision-making by including symptoms not commonly measured in men, such as urinary incontinence, and allow for more frequent assessment of lower urinary tract symptoms thr...
New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia
SRD5A2 is a critical enzyme for prostatic development and growth, and the SRD5A2 inhibitor, finasteride, is used to treat benign prostatic hyperplasia (BPH). SRD5A2 is absent in 30% of normal adult men, which explains the resistance of a subset of patients to this commonly prescribed drug. This project proposes new combination therapies (5-ARI+raloxifene) and evaluates novel non-invasive biomarker...
Frequently Asked Questions About Benign Prostatic Hyperplasia Clinical Trials
Are there benign prostatic hyperplasia clinical trials near me?
Yes, there are 17 benign prostatic hyperplasia clinical trials currently recruiting across 35+ cities in the United States, including Chicago, Illinois; Cleveland, Ohio; Los Angeles, California. Browse the studies above to find one at a location convenient for you.
How do I join a benign prostatic hyperplasia clinical trial?
To join a benign prostatic hyperplasia clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are benign prostatic hyperplasia clinical trials free?
Yes, participation in benign prostatic hyperplasia clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of benign prostatic hyperplasia treatments are being studied?
Current benign prostatic hyperplasia clinical trials are testing a range of approaches across NA (8 studies), PHASE2 (2 studies), PHASE3 (1 study). These include new drugs, combination therapies, medical devices, and other interventions sponsored by 12 research organizations.
Is it safe to participate in benign prostatic hyperplasia clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated July 16, 2026 from ClinicalTrials.gov
About This Data
Data: ClinicalTrials.gov · Source of record for eligibility and locations
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated July 16, 2026 · Data from ClinicalTrials.gov